Urinary buprenorphine concentrations in patients treated with Suboxone® as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay

Journal of Analytical Toxicology

Volumn 32, Issue 7, 2008, Pages 516-521

  Hull, Mindy J ^a   Bierer, Michael F ^a   Griggs, David A ^a   Long, William H ^a   Nixon, Andrea L ^a   Flood, James G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CREATINE; DIAMORPHINE; NORBUPRENORPHINE; OXYCODONE;

ARTICLE; ENZYME IMMUNOASSAY; FEMALE; HEROIN DEPENDENCE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OPIATE ADDICTION; URINALYSIS; URINE;

EID: 50949103681     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/32.7.516     Document Type: Article

References (18)

1. A. Tracqui, P. Kintz, and B. Lucles. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 22: 430-434 (1998).
2. Drug Addiction Treatment Act of 2000 [Page 114 STAT. 1101] Public Law 1 06-31 0 1 06th Congress An Act.
3. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Substance Abuse and Mental Health Services Administration, Rockville, MD, 2004.
4. D. Harris, J. Mendelson, E. Lin, R. Upton, and R. Jones. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone. lin. Pharmacokinet. 43: 329-340 (2004).
5. R. Kronstrand, T.G. Seldén, and M. Josefsson. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 27: 464-470 (2003).
6. F. Vincent, J. Bessard, J. Vacheron, M. Mallaret, and G. Bessard. Determination of buprenorphine and norbuprenorphine in urine and hair by gas chromatography-mass spectrometry. J. Anal. Toxicol. 23: 270-279 (1999).
7. C.W. Hand, K.E. Ryan, S.K. Dutt, R.A. Moore, J. O'Connor, D. Talbot, and H.J. McQuay. Radioimmunoassay of buprenorphine in urine: studies in patients and in a drug clinic. J. Anal. Toxicol. 13: 100-104 (1989).
8. V. Cirimele, P. Kintz, S. Lohner, and B. Ludes. Enzyme immunoassay validation for the detection of buprenorphine in urine. J. Anal. Toxicol. 27: 103-105 (2003).
9. E.I. Miller, H.J. Torrance, and J.S. Oliver. Validation of the Immunalysis microplate ELISA for the detection of buprenorphine and its metabolite norbuprenorphine in urine. J. Anal. Toxicol. 30: 115-119 (2006).
10. M. Böttcher and O. Beck. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J. Anal. Toxicol. 29: 769-776 (2005).
11. P. Puopolo, M. Pothier, S. Volpicelli, and J. Flood. Single procedure for detection, confirmation, and quantification of benzodiazepines in serum by liquid chromatography with photodiode-array detection. Clin. Chem. 37: 701-706 (1991).
12. P. Puopolo, S. Volpicelli, D. Johnson, and J. Flood. Emergency toxicology testing (detection, confirmation, and quantification) of basic drugs in serum by liquid chromatography with photodiode array detection. Clin. Chem. 37: 2124-2130 (1991).
13. E. Gowan and C. Fraser. Despite correlation, random spot and 24-h urine specimens are not interchangeable. Clin. Chem. 33: 1080-1081 (1987).
14. E.J. Cone, R. Lange, and W.D. Darwin. In vivo adulteration: excess fluid ingestion causes false-negative marijuana and cocaine urine test results. J. Anal. Toxicol. 22: 460-473 (1998).
15. A. Fraser and J. Zamecnik. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther. Drug Monit. 25: 723-727 (2003).
16. R. Jones and J. Mendelson. Determination of buprenorphine mass balance. Unpublished clinical study, Reckitt Benckiser report RC980102, 1997.
17. E. Cone, C. Goredetzky, D. Yousefnejad, W. Buchwald, and R. Johnson. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 34: 577-581 (1984).
18. J.J. Kuhlman, Jr., S. Lalani, J. Magluilo, Jr., B. Levine, W.D. Darwin, R.E. Johnson, and E.J. Cone. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J. Anal. Toxicol. 20: 369-378 (1996).